Abstract: A method for promoting expression of calreticulin in at least one kind of eukaryotic cell, and a synthetic peptide useful in this method are provided. In the method provided by the present invention, a culture of target cells is prepared, and a calreticulin expression-promoting peptide having calreticulin expression-promoting activity is supplied at least once to that culture.

Abstract: The present invention provides a method that allows highly efficient and highly reliable evaluation of genomic stability of pluripotent stem cells, a method for removing pluripotent stem cells that have been identified as genomically unstable by the evaluation method from a culture of pluripotent stem cells to be evaluated, and a synthetic peptide that can be used for the methods. The methods provided by the present invention include preparing a culture of pluripotent stem cells of interest and analyzing an expression level of calreticulin for the pluripotent stem cells in the culture followed by identifying genomic stability or genomic instability of the stem cells on the basis of the expression level of calreticulin.

Abstract: A method for promoting expression of calreticulin in at least one kind of eukaryotic cell, and a synthetic peptide useful in this method are provided. In the method provided by the present invention, a culture of target cells is prepared, and a calreticulin expression-promoting peptide having calreticulin expression-promoting activity is supplied at least once to that culture.

Abstract: The present invention provides a method that allows highly efficient and highly reliable evaluation of genomic stability of pluripotent stem cells, a method for removing pluripotent stem cells that have been identified as genomically unstable by the evaluation method from a culture of pluripotent stem cells to be evaluated, and a synthetic peptide that can be used for the methods. The methods provided by the present invention include preparing a culture of pluripotent stem cells of interest and analyzing an expression level of calreticulin for the pluripotent stem cells in the culture followed by identifying genomic stability or genomic instability of the stem cells on the basis of the expression level of calreticulin.

Abstract: The present invention provides a method of screening for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome, comprising the following steps: (a) a step of forming colonies of hematopoietic progenitor cells induced from pluripotent stem (iPS) cells produced from non-T cells in blood mononuclear cells isolated from myelodysplastic syndrome patients, in the presence of a test substance and in the absence of the test substance, and (b) a step of selecting the test substance as a candidate for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome and the like when the colony number in the presence of the test substance increases from the colony number in the absence of the test substance.